Dynavax Nears Final Chapter with Sanofi Acquisition

Dynavax US2681582019

The independent journey of Dynavax Technologies on the public markets is drawing to a definitive close. The biopharmaceutical firm is in the last stages of being acquired by French pharmaceutical giant Sanofi, with final administrative procedures now underway to seal the deal.

Sanofi, operating through its subsidiary Samba Merger Sub, has set the terms for the takeover. The all-cash transaction values Dynavax at approximately $2.2 billion. Shareholders of record are entitled to receive $15.50 for each share they hold.

• Acquisition Price: $15.50 per share (cash)
• Acquiring Entity: Sanofi (via Samba Merger Sub)
• Final Day to Tender Shares: February 9, 2026, at 11:59 PM ET
• Expected Read more...